CN114432456B - 牙科用局部麻醉液 - Google Patents
牙科用局部麻醉液 Download PDFInfo
- Publication number
- CN114432456B CN114432456B CN202111067691.3A CN202111067691A CN114432456B CN 114432456 B CN114432456 B CN 114432456B CN 202111067691 A CN202111067691 A CN 202111067691A CN 114432456 B CN114432456 B CN 114432456B
- Authority
- CN
- China
- Prior art keywords
- local anesthetic
- injection
- steroid
- dental
- cartridge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims abstract description 137
- 150000003431 steroids Chemical class 0.000 claims abstract description 58
- 238000002347 injection Methods 0.000 claims abstract description 53
- 239000007924 injection Substances 0.000 claims abstract description 53
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 20
- 210000000214 mouth Anatomy 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002690 local anesthesia Methods 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 6
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 22
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 15
- 229960003957 dexamethasone Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 11
- 229960004194 lidocaine Drugs 0.000 claims description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 6
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 229960002409 mepivacaine Drugs 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- 239000007951 isotonicity adjuster Substances 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000011232 storage material Substances 0.000 claims description 3
- 206010016326 Feeling cold Diseases 0.000 claims description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 208000035824 paresthesia Diseases 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 54
- 229960005015 local anesthetics Drugs 0.000 abstract description 9
- 230000003444 anaesthetic effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- RETIMRUQNCDCQB-UHFFFAOYSA-N mepivacaine hydrochloride Chemical compound Cl.CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C RETIMRUQNCDCQB-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 229940060365 scandonest Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 3
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 3
- VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229950000812 dexamethasone palmitate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 208000026493 lip paralysis Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229960002660 mepivacaine hydrochloride Drugs 0.000 description 2
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940088542 solu-cortef Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WDPYZTKOEFDTCU-WDJQFAPHSA-N Dexamethasone palmitate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCCCCCCCCCCCCCC)(O)[C@@]1(C)C[C@@H]2O WDPYZTKOEFDTCU-WDJQFAPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RYJIRNNXCHOUTQ-OJJGEMKLSA-L cortisol sodium phosphate Chemical compound [Na+].[Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 RYJIRNNXCHOUTQ-OJJGEMKLSA-L 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940003382 depo-medrol Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960005094 prilocaine hydrochloride Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940087854 solu-medrol Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/1782—Devices aiding filling of syringes in situ
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
问题:提供一种新型牙科用的局部麻醉液,其能够减少将牙科用局部麻醉剂施用于口腔内的患部时,治疗后所引起的患者的不定愁诉,特别是能够减轻口腔周围的不适。解决手段:作为本发明,例如,可以举出一种牙科用局部麻醉用注射液,其是用于在牙科治疗前对口腔内的患部附近进行给药的局部麻醉用注射液,其包含:局部麻醉药;类固醇药;添加剂;和水,或者所述注射液在以上的基础上进一步包含血管收缩药。根据本发明,能够减轻为进行牙科治疗而接受了局部麻醉的患者的治疗后的口腔周围的不适。
Description
技术领域
本发明属于医药品制剂的技术领域。本发明涉及牙科用的局部麻醉液,其是在局部麻醉剂中包含类固醇药的局部麻醉液。
背景技术
对牙齿进行磨削或对牙齿进行外科手术等时,通常,要将局部麻醉剂注射到口腔内的患部附近。另外,有时也向神经所在的区域注射局部麻醉剂,以麻醉神经所延伸的前端部分。这些麻醉方法分别称为浸润麻醉和神经阻滞麻醉。不论是哪一种,在治疗后,患者都可能在口腔周围感到不适。
为了延长作用时间,防止麻醉药向末梢血管转移而被排出,牙科用局部麻醉剂除了利多卡因等的麻醉药之外,多还添加有血管收缩剂(例如,参照非专利文献1)。作为所述血管收缩剂,例如,可以举出肾上腺素(Adrenaline)。此外还包含对羟基苯甲酸酯等的储存剂、pH调整剂等的添加剂。
就在浸润麻醉中使用的牙科用局部麻醉剂而言,在日本,通常提供装有1mL或1.8mL的药液的药筒型。将该药筒装填至专用的注射器中,例如,加装注射针而进行使用。需要说明的是,局部麻醉有手动进行的方法和电动进行的方法。
类固醇是肾上腺皮质激素,具有抑制炎症、抑制免疫、抑制过敏等的作用,被广泛地应用于各种各样的治疗中。类固醇除了锭剂等的口服药剂、软膏等的外用剂之外,也以注射液的形式提供(例如,非专利文献2)。
现有技术文献
非专利文献
[非专利文献1]独立行政法人医药品医疗机器总合机构,“牙科用利多卡因药筒,”2017年1月改订(第13版),[on line],[2020年10月9日检索],网址(https://www.info.pmda.go.jp/go/pack/2710806U1021_3_07/)
[非专利文献2]独立行政法人医药品医疗机器总合机构,“地塞米松注射液1.65mg,”2020年7月改订(第2版),[on line],[2020年10月9日检索],网址(https://www.info.pmda.go.jp/go/pack/2454405H1024_3_04/)
发明内容
本发明所要解决的技术问题
本发明的主要问题是提供一种局部麻醉液,其是一种能够减少将牙科用局部麻醉剂施用于口腔内的患部附近时,在治疗后所引起的患者(大人、儿童)的不定愁诉,特别是口腔周围的不适的新型牙科用的局部麻醉液。
解决技术问题的技术手段
本发明者锐意研究的结果,发现了通过使市售的局部麻醉剂中包含类固醇药,能够很好地解决所述课题,从而完成了本发明。
作为本发明,例如,可以举出下述内容:
[1]、一种牙科用局部麻醉液,其在水溶液中以有效量包含局部麻醉药和类固醇药作为有效成分。
[2]、如所述项[1]所述的牙科用局部麻醉液,其通过以下方式制备:将包含局部麻醉药作为有效成分的牙科用局部麻醉剂的溶液的一部分除去,向残存的该局部麻醉液中补充包含类固醇药作为有效成分的类固醇注射剂溶液。
[3]、如所述项[1]或[2]所述的牙科用局部麻醉液,其中,
所述麻醉液被封入药筒中;或
所述麻醉液被封入药筒中,该药筒装被填至注射器中,或者,所述麻醉液被封入药筒中,该药筒装被填至注射器中,该注射器上进一步安装有注射针。
[4]、如所述项[1]~[3]中任一项所述的牙科用局部麻醉液,其进一步包含血管收缩药。
[5]、如所述项[1]~[4]中任一项所述的牙科用局部麻醉液,其中,
局部麻醉药为利多卡因或其药学上允许的盐,类固醇药为地塞米松或其酯或它们药学上允许的盐。
[6]一种包含局部麻醉药作为有效成分的牙科用局部麻醉液,其用于与类固醇药组合使用。
[7]、一种牙科用局部麻醉液的制造方法,其包含:
除去包含局部麻醉药作为有效成分的牙科用局部麻醉剂的溶液的一部分的工序;和
向除去后残存的该局部麻醉剂溶液中补充包含类固醇药作为有效成分的类固醇注射剂溶液的工序。
发明的效果
根据本发明,能够减轻为了进行牙科治疗而接受了局部麻醉的患者的治疗后的口腔周围的不适。作为所述不适,例如,可以举出唇的麻痹、僵硬、刺痛感、冷感、发痒(特别是儿童)。通过减轻所述不适,特别能够减少儿童在治疗后所表现的咬嘴唇、挠脸颊等行为。
另外,在减轻口腔周围的所述不适的同时,也有能够预防过敏反应、神经不可逆性等的可能性。
附图说明
[图1]表示药筒型的牙科用局部麻醉剂(中央)以及对其进行使用时所使用的麻醉器具的一个例子的照片。
本发明的具体实施方式
1本发明所涉及的局部麻醉液
本发明所涉及的局部麻醉液(以下,称为“本发明的局部麻醉液”)是用于在牙科治疗前对口腔内的患部附近进行给药的局部麻醉用注射液,其在水溶液中以有效量包含局部麻醉药和类固醇药作为有效成分。本发明的局部麻醉液可以通过以下方式制备:将包含局部麻醉药作为有效成分的牙科用局部麻醉剂的溶液的一部分除去,再向残存的该局部麻醉液中补充包含类固醇药作为有效成分的类固醇注射剂溶液。此处,补充的类固醇注射剂溶液的量可以与除去的局部麻醉液的量相同,也可以不同。
另外,本发明的局部麻醉液可以是用于与类固醇药组合使用的、包含局部麻醉药作为有效成分的牙科用局部麻醉液。就该本发明的局部麻醉液而言,其可以与类固醇药以相互独立的形式存在,并非必须包含类固醇药。
1.1局部麻醉药
本发明的局部麻醉液包含局部麻醉药作为有效成分。所述局部麻醉药只要是可以在牙科用治疗中使用并且能溶于水的所谓的钠通道阻滞剂,就无特别限制,可以是短效型,也可以是长效型。具体而言,可以举出:普鲁卡因、丁卡因等的酯型、利多卡因、甲哌卡因、布比卡因、左旋布比卡因、罗哌卡因、丙胺卡因等的酰胺型。其中,优选酰胺型局部麻醉药,特别优选利多卡因、甲哌卡因、丙胺卡因。为了保证水溶性,它们通常以药学上允许的盐的形态提供。作为所述药学上允许的盐,例如,可以举出:盐酸盐、硫酸盐、磷酸盐等的无机酸盐;草酸盐、柠檬酸盐、乳酸盐、琥珀酸盐、苹果酸盐等的有机酸盐。局部麻醉药是盐时,优选利多卡因盐酸盐、甲哌卡因盐酸盐。包含利多卡因盐酸盐的局部麻醉剂例如以牙科用利多卡因(注册商标)药筒、ORA(注册商标)牙科用药筒、Epilido(注册商标)混合注牙科用药筒等的商品名贩卖。包含甲哌卡因盐酸盐的局部麻醉剂例如以Scandonest(注册商标)药筒等的商品名贩卖。包含丙胺卡因盐酸盐的局部麻醉剂例如以Citanest-Octapressin(注册商标)药筒等的商品名贩卖。这些市售品的量为1mL或1.8mL。都可以用于本发明的局部麻醉液。
本发明的局部麻醉液中的局部麻醉药的含量根据局部麻醉药的种类、其他的成分等而有所不同,但在12~40mg/mL的范围内是比较适当的,优选在14~35mg/mL的范围内,更优选在16~30mg/mL的范围内。局部麻醉药为利多卡因时,利多卡因在12~25mg/mL的范围内是比较适当的,优选在14~22mg/mL的范围内,更优选在16~20mg/mL的范围内。虽然不排除比12mg/mL少的含量、比40mg/mL多的含量,但如果比12mg/mL少,则要发挥麻醉作用就可能需要以更多的量进行给药,如果比40mg/mL多,那么某些局部麻醉药可能无法充分溶解。
1.2类固醇药
本发明的局部麻醉液包含类固醇药作为有效成分。所述类固醇药只要是可以在牙科用治疗中使用并且能溶于水的肾上腺皮质激素,就无特别限制。另外,可以是短效型(半衰期:8~12小时)、中效型(半衰期:12~36小时)、长效型(半衰期:36~54小时)中的任一种。具体而言,活性主体例如可以举出:氢化可的松(皮质醇)、可的松、泼尼松龙、甲基泼尼松龙、曲安西龙、地塞米松、倍他米松和它们的酯。作为所述酯,例如可以举出:磷酸酯、琥珀酸酯、醋酸酯、棕榈酸酯。另外,为了保证水溶性,它们通常以药学上允许的盐的形态提供。作为所述药学上允许的盐,例如可以举出:钠盐、钾盐等的碱金属盐;镁盐、钙盐等的碱土类金属盐。其中,优选地塞米松或其酯或其盐,更优选地塞米松磷酸钠。
本发明的局部麻醉液中的类固醇药的含量根据类固醇药的种类、局部麻醉药的种类、其他的成分等而不同,但在1.2~16mg/mL的范围内是比较适当的,优选在1.4~14mg/mL的范围内,更优选在1.6~12mg/mL的范围内。类固醇药为地塞米松时,作为地塞米松,在0.05~1mg/mL的范围内是比较适当的,优选在0.1~0.7mg/mL的范围内,更优选在0.3~0.6mg/mL的范围内。如果低于0.05mg/mL,可能无法充分获得本发明的效果。
基本上少量即可。
1.3血管收缩药
本发明的局部麻醉液可以包含血管收缩药作为有效成分。所述血管收缩药通常是为了促进局部麻醉药在局部滞留,延长作用时间而添加的。作为血管收缩药的具体例,可以举出肾上腺素(Adrenaline)或其药学上允许的盐(例如,酒石酸氢盐)、苯赖加压素。
本发明的局部麻醉液中的血管收缩药的含量,根据局部麻醉药的种类、其他的成分等而有所不同,但在0.005~0.1mg/mL的范围内是比较适当的,优选在0.008~0.05mg/mL的范围内,更优选在0.01~0.02mg/mL的范围内。血管收缩药为肾上腺素时,作为肾上腺素,可以举出与上述相同的含量。
1.4其它
本发明的局部麻醉液可以根据需要而适量包含:药学上允许的储存剂、pH调节剂、等渗剂、增溶剂等的添加剂。
作为储存剂,例如,可以举出:亚硫酸氢钠、焦亚硫酸钠、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯。
作为pH调整剂,例如,可以举出:乳酸、二氧化碳、琥珀酸、葡萄糖酸、柠檬酸、柠檬酸三钠、磷酸、碳酸钾、碳酸氢钠。
作为等渗剂,例如,可以举出:氯化钠、丙三醇、葡萄糖。
作为增溶剂,例如,可以举出:丙二醇、聚乙二醇。
本发明的局部麻醉液,例如,如图1的中央部所示,优选将麻醉液封入牙科局部麻醉用的适当的药筒中。或者,可以是将麻醉液封入该药筒,并将所述药筒装填至专用的注射器中,也可以进一步在以上的基础上安装注射针等。本发明也可包含封入了本发明的局部麻醉液的药筒、注射器、注射针等所组成的试剂盒。
2本发明的局部麻醉液的制造方法和使用方法
本发明的局部麻醉液,例如,可以如下制造。
本发明的局部麻醉液可以通过以下方式制备:除去包含局部麻醉药作为有效成分的牙科用局部麻醉剂的溶液的一部分,向残存的该局部麻醉液中补充包含类固醇药作为有效成分的类固醇注射剂溶液。另外,也可以通过不除去局部麻醉剂的溶液的一部分,而直接将类固醇注射剂溶液追加至局部麻醉液中来制造。或者,也可以通过具有以下两个工序的方法来制造本发明的局部麻醉液:除去包含局部麻醉药作为有效成分的牙科用局部麻醉剂的溶液的一部分的工序;和向除去后残存的该局部麻醉液中补充包含类固醇药作为有效成分的类固醇注射剂溶液的工序。另外,也可以通过例如,向注射用水、纯化水、蒸馏水等的水中,溶解所述的局部麻醉药、类固醇药、应需要的所述的血管收缩药、期望的添加剂,以达到所述的含量的常规方法来制造本发明的局部麻醉液。
局部麻醉药、类固醇药、血管收缩药、添加剂等的用语与上述同义。
作为包含局部麻醉药的牙科用的所述局部麻醉剂,例如,可以举出市售的药筒型牙科用局部麻醉剂(1mL或1.8mL)。市售的药筒型牙科用局部麻醉剂可以直接用来进行制造。此时,市售品中所使用的药筒可以直接沿用。作为所述牙科用局部麻醉剂,例如,可以举出所述的牙科用利多卡因(注册商标)药筒、ORA(注册商标)注牙科用药筒、Epilido(注册商标)混合注牙科用药筒、Scandonest(注册商标)药筒、Citanest-Octapressin(注册商标)药筒。
作为包含类固醇药的所述类固醇注射剂,例如,可以举出可以在牙科中使用的市售的类固醇注射剂。市售的类固醇注射剂可以直接使用。作为所述类固醇注射剂,例如,可以举出:水溶性Hydrocortone(注册商标)注射液(包含氢化可的松磷酸钠)、Solu-Cortef(注册商标)注(包含氢化可的松琥珀酸钠)、Saxizon(注册商标)注(包含氢化可的松琥珀酸钠)、水溶性Predonine(注册商标)注(包含泼尼松龙琥珀酸钠)、Solu-Medrol(注册商标)注(包含甲基泼尼松龙琥珀酸钠)、Depo-Medrol(注册商标)注(包含甲基泼尼松龙醋酸酯)、地塞米松(注册商标)注(包含地塞米松磷酸钠)、Orgadrone(注册商标)注(包含地塞米松磷酸钠)、Limethasone(注册商标)注(包含地塞米松棕榈酸酯)、Rinderon(注册商标)注(包含倍他米松磷酸钠)。
作为除去牙科用局部麻醉剂的溶液的一部分的量,例如,在从市售的药筒型的牙科用局部麻醉剂中除去一部分时,在总容量的1~60%的范围内比较适当,优选在5~50%的范围内,更优选在10~45%的范围内。
补充的类固醇注射剂溶液的量根据使用的局部麻醉剂、类固醇注射剂的种类等而有所不同,但是,例如在除去的局部麻醉剂溶液的量的10~150%的范围内比较适当,优选在20~100%的范围内,更优选在30~60%的范围内。根据需要也可以比10%少,或比150%多。
本发明的局部麻醉液,例如,可以通过常规方法封入牙科局部麻醉用的适当药筒中。此外,也可以将封入有本发明的局部麻醉液的药筒装填至专用的注射器中。并且,也可以进一步装配注射针等。
本发明的局部麻醉液,例如,可以使用市售的手动或电动的麻醉器具,以与市售的药筒型的牙科用局部麻醉剂相同的方式进行使用。具体而言,可以如下使用:以被封入适当的药筒中的状态,被装填至专用的注射器中,装配上注射针,以手动或电动的方式对进行口腔内治疗的患部的周边,以通常在0.8mL~2mL(优选为1mL~1.8mL)的范围内的适当量进行注射。需要说明的是,本发明的局部麻醉液不论大人、儿童,无关性别、年龄(年轻人、老年人)都可以使用。
注射针只要是可以在牙科中使用的即可,无特别限制,作为该针的粗细,例如,可以为30号(G,gauge)左右,具体而言,可以举出在26~32G的范围内的针,优选在28~31G的范围内的针。
本发明的局部麻醉液是用于与类固醇药组合使用的、包含局部麻醉药作为有效成分的牙科用局部麻醉液时,例如,可以将本发明的局部麻醉液(不包含类固醇药)以适当量注射至进行口腔内治疗的患部的周边,然后再将包含类固醇药作为有效成分的类固醇注射剂溶液注射至同一患部周边。另外,也可以将本发明的局部麻醉液(不包含类固醇药)以适当量注射至进行口腔内治疗的患部的周边,接着将包含类固醇药作为有效成分的类固醇注射剂溶液注射至同一患部周边,之后再一次,将本发明的局部麻醉液(不包含类固醇药)以适当量注射至同一患部周边。
为了进行上述的使用,可以将本发明的局部麻醉液(不包含类固醇药)和类固醇注射剂溶液以试剂盒等的形式提供,这样的试剂盒等也是本发明中所包含的。
实施例
以下将举出试验例、实施例等对本发明进行说明,但本发明不限于这些实施例等。
[实施例1]本发明的局部麻醉液的制备(1)
用一次性注射器去除市售的Epilido(注册商标)混合注牙科用药筒1.8mL中的约0.8mL的药液,向药筒内所残存的局部麻醉液约1mL中补充地塞米松(注册商标)注射液3.3mg的药液约0.3mL,制备了本发明的局部麻醉液。所述本发明的局部麻醉液被封入原来的Epilido(注册商标)注射液的药筒内。
[实施例2]本发明的局部麻醉液的制备(2)
代替Epilido(注册商标)混合注牙科用药筒1.8mL,使用了牙科用局部麻醉剂Scandonest(注册商标)药筒3%,以与实施例1同样的方式,制备了本发明的局部麻醉液。
[实施例3]本发明的局部麻醉液的制备(3)
代替Epilido(注册商标)混合注牙科用药筒1.8mL,使用了局部麻醉剂牙科用Citanest-Octapressin(注册商标)药筒,以与实施例1同样的方式,制备了本发明的局部麻醉液。
[试验例1]治疗后的患者的不适减轻效果的验证(1)
将被封入药筒内的实施例1的本发明的局部麻醉液装填至专用的麻醉用注射器中,装配1G、33G或35G的注射针,对患者的左齿肉内进行了注射。另一方面,将只是除去了同样量的Epilido(注册商标),而没有补充地塞米松(注册商标)注射液的局部麻醉液以同样的方式几乎同时地对患者的右齿肉内进行了注射。
其结果,进行了注射的左右齿肉附近的麻醉效果几乎相同,而就注射了包含地塞米松(类固醇药)的本发明的局部麻醉液的左齿肉附近而言,麻醉感在不知不觉间消失,期间,没有患者报告其嘴唇有麻痹等的不适。另一方面,就注射了不包含地塞米松(类固醇药)的以往的局部麻醉液的右齿肉附近而言,大部分的患者报告了其嘴唇麻痹等的不适即使经过3~4小时也没有消失。
另外,单独向患部附近注射包含地塞米松(类固醇药)的本发明的局部麻醉液(约300人),其结果,麻醉感在不知不觉间消失,期间没有患者报告有嘴唇麻痹等的不适。
实施例2和3的本发明的局部麻醉液也获得了同样的结果。
如上所述,本发明的局部麻醉液明显减轻患者在牙科治疗后口腔周围的不适。
[试验例2]治疗后的患者的不适减轻效果的验证(2)
对于10个患者的左颊部(左齿肉内)只给药0.8cc的Citanest-Octapressin(注册商标,丙胺卡因注)或Scandonest(注册商标,甲哌卡因注),而对右颊部(右齿肉内)给药组合了同样的局部麻醉药和0.4cc(100mg/2mL)的Solu-Cortef(注册商标,氢化可的松)的本发明的局部麻醉液,如此进行了牙科治疗。
其结果,就所有患者而言,只给药了该局部麻醉药的左颊部在麻醉解除后也会长期感到异样感(不适、好像要咬到嘴唇的感觉等),而进行了该局部麻醉药和氢化可的松(类固醇药)的组合给药的右颊部并没有报告出现如左颊部般的异样感。并且,所有患者都给出了包含氢化可的松(类固醇药)的本发明的局部麻醉液更好的感想。
[工业实用性]
本发明的局部麻醉液能够减少牙科治疗后的患者的不定愁诉,特别是减轻口腔周围的不适,故而在牙科领域的治疗等中是有用的。
Claims (5)
1.一种注射液在减轻接受了局部麻醉的患者的治疗后的口腔周围的不适的牙科用局部麻醉用注射液的制造中的用途,其中,所述注射液是用于在牙科治疗前对口腔内的患部附近进行给药的局部麻醉用注射液,
所述注射液包含:
选自利多卡因、甲哌卡因、丙胺卡因、以及它们药学上允许的盐中的一种以上的局部麻醉药;
选自氢化可的松、泼尼松龙、甲基泼尼松龙、曲安西龙、地塞米松、倍他米松、它们的磷酸酯、琥珀酸酯、醋酸酯或棕榈酸酯、以及它们药学上允许的盐中的一种以上的类固醇药;
添加剂;以及
水,或者
所述注射液在以上的基础上进一步包含血管收缩药,
所述不适为选自唇的麻痹、僵硬、刺痛感、冷感以及发痒中的至少一种。
2.如权利要求1所述的用途,其中,
所述注射液中,将包含所述局部麻醉药作为有效成分的牙科用局部麻醉液的一部分除去,向残存的该局部麻醉液中补充包含所述类固醇药作为有效成分的类固醇注射液。
3.如权利要求1或2所述的用途,其中,
所述注射液被封入药筒中;或
所述注射液被封入药筒中,该药筒装被填至注射器中,或者,所述注射液被封入药筒中,该药筒装被填至注射器中,该注射器上进一步安装有注射针。
4.如权利要求1或2所述的用途,其中,
所述添加剂选自储存剂、pH调节剂、等渗剂和增溶剂中的一种以上。
5.如权利要求1或2所述的用途,其中,
所述局部麻醉药为利多卡因或其药学上允许的盐,所述类固醇药为地塞米松或其酯或它们药学上允许的盐。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-185536 | 2020-11-06 | ||
JP2020185536A JP6886551B1 (ja) | 2020-11-06 | 2020-11-06 | 歯科用の局所麻酔液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114432456A CN114432456A (zh) | 2022-05-06 |
CN114432456B true CN114432456B (zh) | 2024-02-06 |
Family
ID=76310190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111067691.3A Active CN114432456B (zh) | 2020-11-06 | 2021-09-13 | 牙科用局部麻醉液 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220142915A1 (zh) |
EP (1) | EP3995132A1 (zh) |
JP (1) | JP6886551B1 (zh) |
KR (1) | KR102359793B1 (zh) |
CN (1) | CN114432456B (zh) |
TW (1) | TWI762421B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116239516B (zh) * | 2021-12-07 | 2024-02-20 | 四川大学华西医院 | 一种共晶及其在制备长效镇痛或/和长效局部麻醉的药物中的用途 |
CN116236581B (zh) * | 2021-12-07 | 2023-12-08 | 四川大学华西医院 | 一种具有长效镇痛或/和长效局部麻醉作用的联合用药 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5209724A (en) * | 1988-04-11 | 1993-05-11 | Dhaliwal Avtar S | Composite anesthetic article and method of use |
WO1996034599A1 (en) * | 1995-05-01 | 1996-11-07 | Children's Medical Center Corporation | Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids |
US6426339B1 (en) * | 1996-09-16 | 2002-07-30 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
CN101156942A (zh) * | 2007-09-29 | 2008-04-09 | 刘洪泉 | 治疗复发性口腔溃疡及慢性咽炎的药物组合 |
JP2008524267A (ja) * | 2004-12-22 | 2008-07-10 | メステックス アクチェンゲゼルシャフト | バニロイド受容体作用薬と神経再生物質阻害物質との混合物、鎮痛薬を生成するためのそれらの使用、および該鎮痛薬を適用する方法 |
WO2015103450A1 (en) * | 2014-01-01 | 2015-07-09 | Real Time Imaging Technologies, Llc | Improved local anesthetic solution for dental and/or contrast media use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4124495B2 (ja) * | 1995-03-22 | 2008-07-23 | 天藤製薬株式会社 | 局所麻酔組成物 |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
JP2004521111A (ja) * | 2001-01-25 | 2004-07-15 | ユーロ−セルティーク,エス.エイ. | 局所麻酔薬および使用法 |
JP2006513224A (ja) * | 2002-12-20 | 2006-04-20 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | エステル局所麻酔薬の組み合わせ |
JP4500013B2 (ja) * | 2003-06-20 | 2010-07-14 | 天藤製薬株式会社 | 局所麻酔組成物 |
US20070155755A1 (en) * | 2004-02-23 | 2007-07-05 | Wei Edward T | N-arylshydroxyalkylidene-carboxamide compositions and methods |
US8523569B2 (en) * | 2007-12-28 | 2013-09-03 | Khashayar Kevin Neshat | Controlled release local anesthetic for post dental surgery and method of use |
AU2012241726C1 (en) * | 2011-04-15 | 2017-09-14 | Janssen Pharmaceutica Nv | Freeze dried drug nanosuspensions |
WO2017079734A1 (en) * | 2015-11-05 | 2017-05-11 | University Of Louisville Research Foundation, Inc. | Local and regional anesthesia and analgesia |
US11793621B2 (en) * | 2019-02-27 | 2023-10-24 | Hoodoo Voodoo, LLC. | Dental anesthetic delivery devices and associated methods |
-
2020
- 2020-11-06 JP JP2020185536A patent/JP6886551B1/ja active Active
-
2021
- 2021-07-15 KR KR1020210092595A patent/KR102359793B1/ko active IP Right Grant
- 2021-09-13 EP EP21196268.3A patent/EP3995132A1/en not_active Withdrawn
- 2021-09-13 US US17/473,826 patent/US20220142915A1/en not_active Abandoned
- 2021-09-13 CN CN202111067691.3A patent/CN114432456B/zh active Active
- 2021-09-22 TW TW110135079A patent/TWI762421B/zh active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5209724A (en) * | 1988-04-11 | 1993-05-11 | Dhaliwal Avtar S | Composite anesthetic article and method of use |
WO1996034599A1 (en) * | 1995-05-01 | 1996-11-07 | Children's Medical Center Corporation | Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids |
US6426339B1 (en) * | 1996-09-16 | 2002-07-30 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
JP2008524267A (ja) * | 2004-12-22 | 2008-07-10 | メステックス アクチェンゲゼルシャフト | バニロイド受容体作用薬と神経再生物質阻害物質との混合物、鎮痛薬を生成するためのそれらの使用、および該鎮痛薬を適用する方法 |
CN101156942A (zh) * | 2007-09-29 | 2008-04-09 | 刘洪泉 | 治疗复发性口腔溃疡及慢性咽炎的药物组合 |
WO2015103450A1 (en) * | 2014-01-01 | 2015-07-09 | Real Time Imaging Technologies, Llc | Improved local anesthetic solution for dental and/or contrast media use |
Non-Patent Citations (1)
Title |
---|
Toothache referred from auriculotemporal neuralgia: case report;R. A. Murayama等;《International Endodontic Journal》;20090806;第42卷;第845-851页 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022075019A (ja) | 2022-05-18 |
TW202218658A (zh) | 2022-05-16 |
EP3995132A1 (en) | 2022-05-11 |
KR102359793B1 (ko) | 2022-02-08 |
TWI762421B (zh) | 2022-04-21 |
US20220142915A1 (en) | 2022-05-12 |
CN114432456A (zh) | 2022-05-06 |
JP6886551B1 (ja) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee | Recent advances in topical anesthesia | |
CN114432456B (zh) | 牙科用局部麻醉液 | |
EP1642578B1 (en) | Fentanyl salt composition for nasal administration | |
Haas | An update on local anesthetics in dentistry | |
Ngan et al. | A survey of local and topical anesthesia use by pediatric dentists in the United States | |
Yen et al. | A comparison of fospropofol to midazolam for moderate sedation during outpatient dental procedures | |
CA2914608A1 (en) | Taste masking of anesthetics and analgesics | |
Çalış et al. | Lidocaine versus mepivacaine in sedated pediatric dental patients: randomized, prospective clinical study | |
Bolliger et al. | A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy | |
JP7442023B1 (ja) | 歯科用の局所麻酔用注射液 | |
Al-Khafaji et al. | Unaddressed local anesthesia reversal action of phentolamine mesylate after plain mepivacaine | |
Salma et al. | Use of anesthesia in pediatric dentistry: a cross-sectional survey | |
Logothetis | Local Anesthetic Agents:--A Review of the Current Options for Dental Hygienists. | |
Martínez-Martínez et al. | Use of bufferized dental anesthetics in dental surgery | |
Koerner et al. | Pharmacologic considerations in the management of oral surgery patients in general dental practice | |
Luhmann et al. | Nitrous oxide in the pediatric emergency department | |
Subburu et al. | Efficacy of 7.5% Sodium Bicarbonate Buffered 2% Lidocaine with 1: 80,000 Epinephrine in Exodontia | |
WO2021211575A1 (en) | Compositions comprising propofol, ketamine, and non-opioid analgesic, and methods of use | |
US20120101158A1 (en) | Surface Anesthetic Agent | |
Shetty et al. | ARTICAINE INFILTRATION-A SUBSTITUTE FOR CLASSICAL INFERIOR ALVEOLAR NERVE BLOCK IN LOWER MOLAR EXTRACTIONS: PROSPECTIVE CLINICAL STUDY. | |
WO2009157377A1 (ja) | 口腔内麻酔剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40069388 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |